Octreotide

Octreotide — ADMETatlas

5. Exposure / Absorption

What evidence describes systemic exposure or absorption?

Evidence summary

Measurements

Measurements, observations, and support attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Comparable measurements

Rows suitable for comparison only within matching endpoint and assay context.

Reported observations

Reviewed observations retained without being collapsed into comparable values.

Domain scope

Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.

Bioavailability Tmax Cmax AUC

Bioavailability, AUC, Cmax, and Tmax evidence.

Evidence interpretation

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Bioavailability2 measurements · 2 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	60-63 %	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Route: subcutaneous · Octreotide· 12.3 Pharmacokinetics · bioavailability percent range direct · The relative b...	Open
2	100 %	Comparable	PepTherDia curated product PK field	Route: SC, IV, IM · 36 · Octreotide · exact product name match · field mismatch	Open

Interpretation: Exposure and absorption values should be compared only within matching route, dose, matrix, population, and unit context.

6. Distribution / Barrier

What is known about distribution, binding, permeability, or barrier crossing?

Evidence summary

Measurements

Measurements, observations, and support attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Comparable measurements

Rows suitable for comparison only within matching endpoint and assay context.

Reported observations

Reviewed observations retained without being collapsed into comparable values.

Domain scope

Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.

Plasma protein binding BBB penetration Vd

Distribution volume, plasma protein binding, permeability, and BBB penetration evidence.

Evidence interpretation

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Vd4 measurements · 4 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	21.6 L	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Octreotide· 12.3 Pharmacokinetics · volume of distribution vdss estimated to be · In pati...	Open
2	21.6 L	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Octreotide· 12.3 Pharmacokinetics · volume of distribution vdss estimated to be · The Vds...	Open
3	13.6 L	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma	Octreotide· 12.3 Pharmacokinetics · volume of distribution estimated to be · Distribution...	Open
4	13.6 L	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma	Octreotide· 12.3 Pharmacokinetics · volume of distribution estimated to be · In healthy v...	Open

Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA

artificial membrane

Caco-2

cell monolayer

MDCK

cell monolayer

RRCK

Interpretation: Distribution, protein binding, PAMPA, cell-monolayer, and BBB evidence are not interchangeable without matching assay/model context.

7. Metabolic & Proteolytic Stability

How stable is the peptide in biological matrices or protease systems?

Evidence summary

Measurements

Measurements, observations, and support attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Comparable measurements

Rows suitable for comparison only within matching endpoint and assay context.

Reported observations

Reviewed observations retained without being collapsed into comparable values.

Domain scope

Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.

Serum/plasma stability

Serum/plasma stability and protease stability evidence.

Evidence interpretation

The same three research-facing layers are used across ADMETatlas.

Comparable measurements

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Serum/plasma stability5 measurements · 5 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	6840 seconds	Comparable	Liquid scintillation counting · rat · Injected into mesenteric veins rat	Dose/window: 2 nmol · Time: 2 hours · Rat plasma proteases · in vivo	Open
2	4320 seconds	Comparable	Liquid scintillation counting · rat · Injected into mesenteric veins rat	Dose/window: 2 nmol · Time: 2 hours · Rat plasma proteases · in vivo	Open
3	90 minutes 5400 seconds	Comparable	natural · human · Human plasma	Dose/window: 500 μg/ml · Time: Blood sample collected after 15-60 minutes · Proteases from Human plasma · in vivo	Open
4	90 minutes 5400 seconds	Comparable	natural · human · Human serum	Dose/window: 30 ng/kg/min · Time: 60 minutes · Human serum proteases · in vivo	Open
5	144 ±15 minutes 8640 seconds	Comparable	Radioimmunoassay · human · (Dose s/c injected)Human plasma (type 1diabetic patients)	Dose/window: 50 μg · Time: Blood collected 12hours after peptide injection · Proteases from Human plasma (type 1 diabetic patients) · in vivo	Open

Interpretation: In vitro stability, protease stability, and percent-remaining measurements are not collapsed into one value.

8. Excretion / Persistence

What evidence describes clearance or persistence?

Evidence summary

Measurements

Measurements, observations, and support attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Comparable measurements

Rows suitable for comparison only within matching endpoint and assay context.

Reported observations

Reviewed observations retained without being collapsed into comparable values.

Domain scope

Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.

Half Life Clearance

Clearance and half-life evidence.

Evidence interpretation

The same three research-facing layers are used across ADMETatlas.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Clearance10 measurements · 6 comparable · 4 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	8.3 L/h	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Octreotide· 12.3 Pharmacokinetics · clearance single · In normal subjects, octreotide hal...	Open
2	8.4 L/h	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Octreotide· 12.3 Pharmacokinetics · clearance single · Patients with liver cirrhosis show...	Open
3	~ 4.5 L/h	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Octreotide· 12.3 Pharmacokinetics · octreotide lar dialysis clearance · In patients with...	Open
4	7.3-8.8 L/h	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Octreotide· 12.3 Pharmacokinetics · octreotide lar renal impaired clearance range · The c...	Open
5	7-10 L/h	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma	Octreotide· 12.3 Pharmacokinetics · clearance ranged from to · Distribution In healthy vo...	Open
6	10 L/h	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma	Octreotide· 12.3 Pharmacokinetics · clearance single · In healthy volunteers, the distrib...	Open
7	Observation In an elderly population, dose adjustments may be necessary due to a significant increase in the half-life (46%) and a significant decrease in the clearance (26%) of the drug.	Reported	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Octreotide· 12.3 Pharmacokinetics · clearance elderly relative decrease text · In an elde...	Open
8	Observation In an elderly population, dose adjustments may be necessary due to a significant increase in the half-life (46%) and a significant decrease in the clearance (26%) of the drug.	Reported	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Octreotide· 12.3 Pharmacokinetics · clearance elderly relative decrease text · In an elde...	Open
9	Observation The relative decrease in clearance with doses above 600 mcg/day is not defined.	Reported	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Octreotide· 12.3 Pharmacokinetics · clearance relative decrease not defined text · The re...	Open
10	Observation Clearance was reduced by about 66% suggesting nonlinear kinetics of the drug at daily doses of 600 mcg/day compared to 150 mcg/day.	Reported	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Octreotide· 12.3 Pharmacokinetics · clearance relative reduction text · Clearance was red...	Open

Interpretation: Clearance and half-life require route, matrix, species/population, and time-scale context before comparison.

Evidence landscape and measurement index

Evidence landscape

A cross-domain view of where evidence is concentrated, which interpretation layers dominate, and how traceable the measurements are.

ADMET domain

Comparable

Reported

Contextual

Exposure / Absorption

20 measurements

Distribution / Barrier

12 measurements

Metabolic & Proteolytic Stability

5 measurements

Excretion / Persistence

13 measurements

Toxicity / Safety

0 measurements

Endpoint distribution

Top evidence-bearing endpoint questions.

Max Concentration

Clearance

Plasma Protein Binding

Serum Plasma Stability

Time To Max Concentration

Volume Of Distribution

Blood Brain Barrier Penetration

Half Life

Assay context

Broad context buckets, useful before comparing values.

In vivo / route

Matrix / stability

Clinical / product

Traceability

Reference-link availability for measurement-level audit.

Linked reference

Not linked

All evidence index

Every measurement remains available for audit and drilldown. Counts describe evidence volume, not confidence.

DomainLayerReferenceSpeciesMatrixRoute

#	ADMET domain	Endpoint	Reported value	Evidence layer	Assay / model	Condition	Reference
1	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	6,840 seconds	Comparable	Liquid scintillation counting · rat · Injected into mesenteric veins rat	Time: 2 hours · Dose/window: 2 nmol · Protease: Rat plasma proteases · in vivo	Open
2	Excretion / Persistence Persistence	Half Life	113 minutes 6,780 seconds	Comparable	natural · Patients with severe renal impairment	Dose/window: 125 μg/kg · Protease: Patient blood proteases · in vivo	Open
3	Excretion / Persistence Persistence	Half Life	37.7 Minutes 2,262 seconds	Comparable	MALDI-TOF-MSI and LC-MS/MS · mouse · Mouse intestine tissue lysate	Route: Intragastrical (i.g.) · Time: The mice were sacrificed at 10, 20, 40, 60, 120, 240 and 360 min · Dose/window: 50 mg/kg · Protease: Mouse intestine tissue lysate protease · In Vivo	Open
4	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	90 minutes 5,400 seconds	Comparable	natural · human · Human serum	Time: 60 minutes · Dose/window: 30 ng/kg/min · Protease: Human serum proteases · in vivo	Open
5	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	90 minutes 5,400 seconds	Comparable	natural · human · Human plasma	Time: Blood sample collected after 15-60 minutes · Dose/window: 500 μg/ml · Protease: Proteases from Human plasma · in vivo	Open
6	Excretion / Persistence Persistence	Half Life	28 Minutes 1,680 seconds	Comparable	HPLC-MS · mouse · Mouse stomach tissue lysate	Route: Intragastrical (i.g.) · Time: The mice were sacrificed at 10, 20, 40, 60, 120, 240 and 360 min · Dose/window: 50 mg/kg · Protease: Mouse stomach tissue lysate protease · In Vivo	Open
7	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	4,320 seconds	Comparable	Liquid scintillation counting · rat · Injected into mesenteric veins rat	Time: 2 hours · Dose/window: 2 nmol · Protease: Rat plasma proteases · in vivo	Open
8	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	144 ±15 minutes 8,640 seconds	Comparable	Radioimmunoassay · human · (Dose s/c injected)Human plasma (type 1diabetic patients)	Time: Blood collected 12hours after peptide injection · Dose/window: 50 μg · Protease: Proteases from Human plasma (type 1 diabetic patients) · in vivo	Open
9	Distribution / Barrier Distribution	Plasma Protein Binding	65 %	Comparable	PepTherDia curated product PK field · plasma protein	Route: SC, IV, IM	Open
10	Exposure / Absorption Exposure	Bioavailability	100 %	Comparable	PepTherDia curated product PK field	Route: SC, IV, IM	Open

1–10 / 50

Identity & reference map

Summary11 reference groups

Identity type: canonical sequence
Reported notation: 1
Reference groups: 11
Measurements: 50
ATL peptide ID: ATLPC0025642

Identity concordance

Exact reported notation

Reported sequence string matches the current peptide notation.

12 / 12

Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 12

Different notation

Reported notation does not resolve to the current display sequence.

0 / 12

Reference map11 of 11 shown

Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

Reference	Supports	Reported identity	Records
Reference link Open	DistributionExposurePersistence Area Under Curve, Bioavailability, Clearance, Max Concentration +3 more	No reported alias	0 identity 25 evidence
Reference link Open	DistributionExposurePersistence Area Under Curve, Clearance, Max Concentration, Plasma Protein Binding +2 more	No reported alias	0 identity 12 evidence
PubMed 8020889 Open	Stability Serum Plasma Stability	No reported alias FCFWKTCTexact	2 identity 2 evidence
PubMed 8289671 Open	Stability Serum Plasma Stability	No reported alias FCFWKTCTexact	2 identity 2 evidence
Reference link Open	Distribution Blood Brain Barrier Penetration	No reported alias FCFWKTCTexact	2 identity 2 evidence
Reference link Open	DistributionExposure Bioavailability, Plasma Protein Binding	No reported alias FCFWKTCTexact	1 identity 2 evidence
PubMed 7911441 Open	Persistence Half Life	No reported alias FCFWKTCTexact	1 identity 1 evidence
PubMed 28010844 Open	Persistence Half Life	No reported alias FCFWKTCTexact	1 identity 1 evidence
PubMed 28010844 Open	Persistence Half Life	No reported alias FCFWKTCTexact	1 identity 1 evidence
PubMed 2687064 Open	Stability Serum Plasma Stability	No reported alias FCFWKTCTexact	1 identity 1 evidence

1–10 / 11

Interpretation: Reference links and reported notations help confirm that measurements point to the same peptide identity or a compatible peptidoform. ADMET interpretation still belongs to the endpoint modules above, where assay/model and condition context are shown with each measurement.

Data access & reproducibility

Record scopePublic release

ATL peptide ID: ATLPC0025642
Identity type: canonical sequence
ADMET endpoints: 10
Measurements: 50
Reference groups: 11
Release view: Public release

Analysis-ready files

Peptide record

TSV

Identity, sequence, profile-level fields, and current release view metadata.

Download record

Programmatic access

The request returns the same structured peptide record used by this profile. Measurement downloads use the same peptide identifier and public release visibility.

Open endpoint

GET /api/v1/peptides/ATLPC0025642

open

curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0025642' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'

Interpretation: Use these files as the reproducible data package for this peptide profile. Cross-peptide comparison still depends on compatible endpoints, assays, species or model systems, route, dose, matrix, and evidence layer.

#	Value	Evidence layer	Assay / model	Condition	Reference
1	Observation Peak concentrations and area under the curve (AUC) values were dose proportional after IV single doses up to 200 mcg and subcutaneous single doses up to 500 mcg and after subcutaneous multiple doses up to 500 mcg 3 times a day (1,500 mcg/day).	Reported	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Route: subcutaneous · Octreotide· 12.3 Pharmacokinetics · cmax auc dose proportionality text · Peak concentrati...	Open
2	Observation Peak concentrations and area under the curve (AUC) values were dose proportional both after subcutaneous or intravenous single doses up to 400 mcg and with multiple doses of 200 mcg 3 times daily (600 mcg/day).	Reported	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Route: subcutaneous · Octreotide· 12.3 Pharmacokinetics · cmax auc dose proportionality text · Peak concentrati...	Open

Cmax12 measurements · 9 comparable · 3 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	5.2 ng/mL	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Octreotide· 12.3 Pharmacokinetics · cmax peak concentration of value · Peak concentration...	Open
2	5.2 ng/mL	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Octreotide· 12.3 Pharmacokinetics · cmax peak concentration of value · Peak concentration...	Open
3	1.6 ng/mL	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Octreotide· 12.3 Pharmacokinetics · octreotide lar steady state peak 20mg · The steady-st...	Open
4	2.6 ng/mL	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Octreotide· 12.3 Pharmacokinetics · octreotide lar steady state peak 30mg · The steady-st...	Open
5	0.3 ng/mL	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Octreotide· 12.3 Pharmacokinetics · octreotide lar transient day1 peak 10mg · The transie...	Open
6	0.8 ng/mL	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Octreotide· 12.3 Pharmacokinetics · octreotide lar transient day1 peak 20mg · The transie...	Open
7	1.3 ng/mL	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Octreotide· 12.3 Pharmacokinetics · octreotide lar transient day1 peak 30mg · The transie...	Open
8	2.8 ng/mL	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Route: subcutaneous · Octreotide· 12.3 Pharmacokinetics · cmax mean peak concentration of value · A mean peak c...	Open
9	2.8 ng/mL	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Route: subcutaneous · Octreotide· 12.3 Pharmacokinetics · cmax mean peak concentration of value · In patients w...	Open
10	Observation Plateau concentrations were maintained over a period of nearly 2 to 3 weeks, showing dose proportional peak concentrations of about 0.07 ng/mL/mg.	Reported	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Octreotide· 12.3 Pharmacokinetics · cmax dose proportional peak text · Plateau concentrat...	Open

1–10 / 12

Tmax4 measurements · 4 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	0.4 hours 1440 seconds	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Octreotide· 12.3 Pharmacokinetics · tmax peak concentration were reached · Peak concentra...	Open
2	0.4 hours 1440 seconds	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Octreotide· 12.3 Pharmacokinetics · tmax peak concentration were reached · Peak concentra...	Open
3	0.7 hours 2520 seconds	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Route: subcutaneous · Octreotide· 12.3 Pharmacokinetics · tmax mean peak concentration reached in · A mean peak...	Open
4	0.7 hours 2520 seconds	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Route: subcutaneous · Octreotide· 12.3 Pharmacokinetics · tmax mean peak concentration reached in · In patients...	Open

Plasma protein binding5 measurements · 5 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	~ 65 %	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human · blood	Octreotide· 12.3 Pharmacokinetics · plasma binding bound in plasma about percent · In blo...	Open
2	~ 65 %	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human · blood	Octreotide· 12.3 Pharmacokinetics · plasma binding bound in plasma about percent · In blo...	Open
3	41.2 %	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma	Octreotide· 12.3 Pharmacokinetics · mean percent drug bound · The mean percent of the dru...	Open
4	41.2 %	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma	Octreotide· 12.3 Pharmacokinetics · mean percent drug bound · The mean percent of the dru...	Open
5	65 %	Comparable	PepTherDia curated product PK field · plasma protein	Route: SC, IV, IM · 36 · Octreotide · exact product name match · field mismatch	Open

BBB penetration3 measurements · 1 comparable · 2 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	5.2 x 10^-6 cm/s	Comparable	BMEC · blood-brain barrier	Pe · paracellular	Open
2	9 μL/min	Reported	BMEC · blood-brain barrier	Clt · paracellular	Open
3	Observation source reported BBB observation	Reported	NA · NA · NA · blood-brain barrier	Route: NA · NA	Open

Half Life3 measurements · 3 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	28 Minutes 1680 seconds	Comparable	HPLC-MS · mouse · Mouse stomach tissue lysate	Route: Intragastrical (i.g.) · Dose/window: 50 mg/kg · Time: The mice were sacrificed at 10, 20, 40, 60, 120, 240 and 360 min · Mouse stomach tissue lysate protease · In Vivo	Open
2	37.7 Minutes 2262 seconds	Comparable	MALDI-TOF-MSI and LC-MS/MS · mouse · Mouse intestine tissue lysate	Route: Intragastrical (i.g.) · Dose/window: 50 mg/kg · Time: The mice were sacrificed at 10, 20, 40, 60, 120, 240 and 360 min · Mouse intestine tissue lysate protease · In Vivo	Open
3	113 minutes 6780 seconds	Comparable	natural · Patients with severe renal impairment	Dose/window: 125 μg/kg · Patient blood proteases · in vivo	Open

Octreotide

Peptide developability profile

1. Sequence & peptidoform

Sequence interpretation

2. Structure & chemistry

Structure and chemistry interpretation

3. Physicochemical profile

Computed descriptors

Computed developability descriptors

4. Product context

Translational product context

5. Exposure / Absorption

Evidence summary

6. Distribution / Barrier

Evidence summary

7. Metabolic & Proteolytic Stability

Evidence summary

8. Excretion / Persistence

Evidence summary

9. Evidence landscape

Evidence landscape and measurement index

10. Identity & reference map

Identity & reference map

11. Data access & reproducibility

Data access & reproducibility

Peptide record

Evidence table

Structured record